Valeant Targets Cesamet On Breast Cancer As It Waits For Pain Claim
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
While a chemotherapy-induced neuropathic pain indication is in development, Valeant is relaunching the synthetic cannabinoid Cesamet with a new strategy for its approved antiemetic use that will focus on physicians treating breast cancer at high-volume teaching institutions, President-Valeant North America/R&D Wesley Wheeler told a May 1 earnings call